Abbott Laboratories Q2 2026 Earnings Analysis

UnitedHealth Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)] ────────── **BETA FINCH — UnitedHealth Group (UNH) Q2 2026 Earnings Breakdown** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into UnitedHealth Group's second quarter 2026 results — a quarter that, honestly, marks a pretty big turnaround story. JORDAN: Big turnaround is right. But before we get into it — quick reminder for everyone listening. ALEX: Right, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good, now let's get into it. ALEX: So let's start with the headline numbers, because they're strong. Adjusted EPS came in at $6.38, up from $4.08 a year ago — that's a huge jump. Revenue was about $112 billion, roughly flat year-over-year, but operating earnings grew 55%. And they raised full-year guidance to a range of $19.50 to $20 a share. JORDAN: What jumps out to me is the medical care ratio — that's basically the percentage of premium revenue that goes out the door in medical claims. It dropped to 86.7% from 89.4% last year. Lower is better for the insurer. Part of that is $860 million in favorable prior-period development, meaning they overestimated costs in prior periods and get to release some of that reserve now. But even stripping that out, the underlying trend is improving. ALEX: And this is really the story CEO Stephen Hemsley told at the top of the call — this is a company about a year into a restructuring after a rough stretch, and he was pretty clear: "we will remain restless." He's not declaring victory, but the discipline is showing up in the numbers. JORDAN: Let's talk segments, because the picture is genuinely split. Medicare Advantage was the star of the quarter. Membership retention beat expectations, they now expect MA enrollment to decline by only about 1.1 million instead of more, and Medicare margins are tracking above 3% for the year. Medical trend also came in below their original 10% estimate — helped by benefit redesign, network curation, and honestly, a milder flu season. ALEX: Meanwhile, commercial is the soft spot. Cost trends are running modestly above 11%, worse than they'd hoped. Management pointed to two specific culprits: the No Surprises Act's arbitration process — which they say is being exploited, with average payouts to out-of-network providers now 11 times what Medicare would pay — and more aggressive provider billing and coding practices. JORDAN: That arbitration point was one of the more eye-opening moments in the Q&A. Executive Dan Kueter said roughly 60% of all arbitration cases are now brought by just five entities, and 40% of claims entering the process are actually ineligible to begin with. It's clogging the system and driving costs up. The upshot: commercial margin recovery, which they'd hoped to complete by 2027, is now going to take longer. Not derailed, in their words — just delayed. ALEX: Medicaid, meanwhile, is basically playing out as planned — margins pressured, expected to land between -1% and -1.7% for the year, as state reimbursement rates lag behind medical cost growth. Nothing new there, just a slow grind toward better alignment with states. JORDAN: Now let's flip to Optum, the services side of the business, because that's where a lot of the AI story lives. Optum Health — their value-based care arm — is showing real improvement: a roughly 10% reduction in hospitalizations in regions where they've rolled out new care transition programs, and patient satisfaction up about 5% year-over-year. ALEX: Optum Rx, the pharmacy benefit manager, is leaning hard into transparency — they're on track to have more than 95% of clients on 100% rebate pass-through by year-end. This episode includes AI-generated content.

Prologis Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the calls that move markets and make sense of the numbers behind them. I'm Alex. JORDAN: And I'm Jordan. Today we're digging into Prologis — ticker PLD — the industrial and logistics real estate giant, reporting their second quarter of 2026. ALEX: Before we jump in, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Okay, with that out of the way, Alex, this was a strong quarter for Prologis. Where do we start? ALEX: Let's start with the headline numbers. Core FFO came in at $1.63 per share including promote income, $1.60 without — both ahead of expectations. And because of that strength, they raised full-year guidance: Core FFO now expected between $6.22 and $6.30 per share, and net earnings guidance up to $4.40 to $4.55 per share. JORDAN: And it's not just a beat-and-raise on the bottom line — the operational metrics back it up. Occupancy hit 95.5%, up 20 basis points from Q1. Same-store NOI growth was 6.4% net effective and 8.5% on a cash basis. Those are really healthy numbers for a REIT this size. ALEX: The leasing volume stood out to me the most — 67 million square feet signed in the quarter. CEO Dan Letter called it their fourth record in seven quarters. JORDAN: Right, and it's paired with 66 million square feet of net absorption in the US, the highest since 2022. Vacancy dropped to 7.2%, market rents ticked up about 70 basis points. Management's whole thesis this call was that the industrial market has moved past its "inflection phase" and into what they're calling the next phase of growth. ALEX: There's also a really interesting structural story here beyond just warehouses. Prologis has been building out data centers and energy as parallel growth engines using the same land and customer relationships. JORDAN: Yeah, the numbers there are eye-popping. Their power pipeline is now 5.8 gigawatts — that's more than doubled in two years. Depending on how much of that gets built as basic "powered shell" versus fully finished "turnkey" data centers, that represents somewhere between $17 billion and $87 billion of potential investment. ALEX: Huge range. JORDAN: Huge range, and CEO Dan Letter was upfront on the call that it's genuinely hard to predict where in that range they'll land — it depends on customer preference. But they did share they've now started nearly $4 billion of data center development, all build-to-suit for hyperscale customers, and they sold a 100-megawatt power land parcel this quarter at an 82% margin. ALEX: Which tells you how profitable just the land and power entitlement piece of this business can be, even before construction. JORDAN: Exactly — and CFO Tim Arndt mentioned they see over 10 gigawatts of opportunity over the next decade. It's basically a second growth business layered on top of the core logistics platform. ALEX: On the guidance side, they raised development starts to a range of $5.5 to $6.5 billion, and increased acquisitions guidance too — they bought $1.8 billion of real estate this quarter at roughly a 20% discount to replacement cost. JORDAN: That IRR discipline came up a few times. Management noted underwritten IRRs on acquisitions have beaten IRRs on dispositions by 140 basis points year to date — so they're actively upgrading the portfolio, not just growing for growth's sake. ALEX: Now, one thing listeners should know — there's a corporate development angle hovering over this whole call that management wouldn't discuss. JORDAN: Right, Prologis has made a possible offer for Segro, a UK logistics REIT, under UK takeover rules. Because of regulatory restrictions, they explicitly said they couldn't answer any que This episode includes AI-generated content.

Abbott Laboratories Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)], INCOME (https://betafinch.com/groups/INCOME) [https://betafinch.com/groups/INCOME)] ────────── Welcome to Beta Finch, your AI-powered earnings breakdown. Here's the Abbott Labs (ABT) Q2 2026 script. --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into Abbott Laboratories' second quarter 2026 results. Before we jump in, quick disclaimer — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Thanks, Alex. And there's a lot to like in this print. Let's start with the headline numbers. **ALEX:** Right, so Abbott posted sales growth of 4.8% for the quarter — that's an acceleration from the last two quarters — and adjusted EPS of $1.31, which beat both the midpoint of their guidance and consensus estimates. **JORDAN:** And here's the part investors really zeroed in on — Abbott didn't just reaffirm full-year sales guidance of 6.5% to 7.5%, they actually raised their EPS guidance range to $5.45 to $5.60. CEO Robert Ford was pretty clear that gross margin expansion is doing a lot of the heavy lifting there — margins came in at 58%, up 100 basis points year-over-year. **ALEX:** Let's talk segments, because there's a real story of divergence here. Medical devices grew 8.5%, led by electrophysiology — that's the heart rhythm and ablation business — which grew in the low teens. EPD, their emerging markets pharma division, grew 9%, powered by India, Latin America, and Southeast Asia. **JORDAN:** Diagnostics was mixed. Core lab was strong, U.S. up 7.5%. But rapid and molecular diagnostics — that's respiratory testing — declined 8% because it was just a weak flu and respiratory virus season. That's expected and temporary though, not a demand problem. **ALEX:** And then nutrition — this is the comeback story of the quarter. Sales came in ahead of expectations for the second straight quarter, up sequentially by $125 million. Ensure retail consumption in the U.S. is up double digits. **JORDAN:** Yeah, that's the price increases from late last year finally working through the system — volumes are responding well now that consumers have adjusted. Management is now framing nutrition as a sustainable 2-4% grower going forward. **ALEX:** Let's get into the strategic stuff, because there's a lot of pipeline news. Abbott completed enrollment in its coronary IVL trial, filed with the FDA for the Amulet 360 left atrial appendage device, and got a CE mark in Europe for Libre Duo — which is notable, it's the world's first dual glucose-ketone monitoring sensor, designed to help prevent diabetic ketoacidosis. **JORDAN:** The CGM story is worth sitting with for a second. Diabetes care crossed $2 billion in quarterly sales, growing 9.5%. Now, one analyst on the call kind of poked at that number as "only" 9.5%, and Ford pushed back — reasonably, I'd say. He pointed out there's 75 to 80 million people globally who could realistically use a CGM, and only 15 million currently do. Growth right now is basically waiting on reimbursement expansion, especially the big one: U.S. Type 2 non-insulin Medicare coverage, which could unlock roughly 10 million beneficiaries. Ford said that could happen this fall but wouldn't pin down an exact date. **ALEX:** They're also planning a fifth manufacturing facility for CGM sensors — a billion-dollar investment — because they expect to hit capacity limits at their current facility within a couple years. That's a pretty strong signal of how bullish they are on long-term demand. **JORDAN:** One theme that came up repeatedly in the Q&A was this investor worry about decelerating hospital procedure volumes — tied to ACA enrollment changes and Medicaid dynamics. This episode includes AI-generated content.

General Electric Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: INDUSTRIALS (https://betafinch.com/groups/INDUSTRIALS) [https://betafinch.com/groups/INDUSTRIALS)] ────────── Welcome to Beta Finch, your AI-powered earnings breakdown of the companies moving the market. I'm about to walk through GE Aerospace's Q2 2026 results. ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, here with Jordan, and today we're digging into GE Aerospace's second quarter 2026 numbers. Before we get into it — quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And GE Aerospace gave us a lot to talk about this quarter, Alex. This wasn't just a beat — they raised guidance across the board. ALEX: Right, let's start with the headline numbers. Orders up 17%, revenue up 24% — that's the fifth straight quarter of at least 20% revenue growth — operating profit up 18%, EPS up 22% to $2.02, and free cash flow jumped 43% to $3 billion. JORDAN: That free cash flow number really stood out to me. They actually reduced working capital even while earnings grew 24%. CFO Rahul Ghai called that out specifically — better receivables, better inventory management. That's not easy to pull off when you're scaling this fast. ALEX: And both segments contributed. Commercial Engines and Services, or CES, was up 27% in revenue, and Defense and Propulsion, DPT, grew 16%. CES margins did dip about 130 basis points to 21.7%, but that's from investing in installed engine growth — basically the cost of feeding future services revenue. JORDAN: Which is the classic GE Aerospace story right now — sell more engines at lower margin today, because those engines come back for decades of high-margin maintenance work. Their backlog is over $210 billion total, with $170 billion of that in commercial services alone. ALEX: So given all that strength, they raised full-year guidance pretty significantly. Revenue now expected to grow high teens, up from low double digits. EPS guidance moved to $7.65 to $7.85, and free cash flow guidance jumped to $8.9 to $9.2 billion. JORDAN: What's interesting is CEO Larry Culp explained why they didn't raise guidance last quarter despite a strong Q1 — there was real geopolitical and demand uncertainty back in April. He said flat out, "we would play April all over again in the same way." They wanted to see how customer behavior actually played out before getting ahead of themselves. ALEX: And it turns out demand held up remarkably well. Culp mentioned parked CFM56 aircraft have actually declined since March, and departures — which were roughly flat in the first half — are expected to gradually pick back up in the second half. JORDAN: The demand side really isn't the constraint here anymore. Multiple times on the call, both Culp and Ghai said this is now a supply-side story, not a demand-side one. Spare parts delinquencies — meaning shipments delayed due to material availability — were actually up 20% sequentially, even as they're growing spare parts revenue over 25%. ALEX: That's a good problem to have, but still a real constraint. They talked about using their "Flight Deck" operational system to chip away at it — things like a Kaizen event with supplier GKN that led to a 90% improvement in inspection time, and AI-driven demand signal processing that cut processing time by nearly 90% across 190 parts. JORDAN: And on the product side, a big milestone — they certified the LEAP-1B durability kit, which should roughly double time on wing. That's huge for airlines worried about engine cost of ownership, which came up multiple times in the Q&A. Analysts pushed hard on whether airlines can keep absorbing these costs. ALEX: Culp's answer was essentially: we hear you, we're not taking a victory lap, but we're doing everything we can short-term — like getting LEAP This episode includes AI-generated content.

Morgan Stanley Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: BANKS (https://betafinch.com/groups/BANKS) [https://betafinch.com/groups/BANKS)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Morgan Stanley's second quarter 2026 results — and Jordan, this one's got some genuinely eye-popping numbers. JORDAN: It really does. But before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. ALEX: Right, let's get into it. Morgan Stanley posted record revenues of $21.3 billion for the quarter, with EPS of $3.46 — both records. First half of the year, they're at $42 billion in revenue and a 27% return on tangible common equity. That's an exceptional run. JORDAN: And it wasn't just one business carrying the load. Institutional Securities hit a record $11 billion in revenue, driven by an absolutely blowout equities quarter — $6.3 billion, up across every product and region, with Asia standing out. Investment banking revenue jumped 58% year-over-year to $2.4 billion. ALEX: That IPO market really came alive this quarter too, which fed directly into Wealth Management. They added a record $148 billion in net new assets — and CFO Sharon Yeshaya pointed out that stock plan and IPO flows made up just over half of that. Total client assets across Wealth and Investment Management now sit at $10 trillion, which CEO Ted Pick called out as a milestone the firm's been chasing for a while. JORDAN: The wealth management pre-tax margin came in at 30.5%, also a record. And there was a nice shareholder-friendly move — a 15% dividend increase to $1.15 per share, plus $1.5 billion in buybacks. Their CET1 capital ratio is at 14.8%, giving them roughly 300 basis points of excess capital cushion. ALEX: That capital question actually drove one of the more interesting exchanges in the Q&A. An analyst asked Pick point blank — why keep sitting on all this excess capital instead of deploying it more aggressively? His answer was basically: there's real client demand for that capital across every business line, and they'd rather feed the organic growth machine first. He didn't rule out bolt-on acquisitions, but said the bias is clearly toward organic investment right now. JORDAN: The moment that stood out most to me, though, was when Mike Mayo asked about the AI capital expenditure supercycle. Pick actually put real numbers on it — data center CapEx forecasts for 2026 have jumped from an initial $575 billion estimate to about $850 billion actually coming in. For 2027, projections have gone from $700 billion to $1.3 trillion. And he floated a longer-term thesis, using their research team's framework, that the AI compute buildout could eventually reach something like $10 trillion — but stressed we're only maybe 10 to 15% of the way through that cycle. ALEX: He was pretty careful to caveat that, though — called it a "known unknown" and said the numbers could shift dramatically based on chip innovation, geopolitics, supply chains. He wasn't trying to make it sound like a sure thing. JORDAN: Right, and that ties into the second big theme he flagged — the return of geopolitics as a force reshaping supply chains and capital allocation. When Gerard Cassidy asked what could make this AI-driven boom crack, Pick's answer was refreshingly candid — he referenced the dot-com bubble and the SPAC boom, and said the firm's watching closely for froth. Their mantra, as he put it, is "higher highs, but also higher lows" — meaning they want durability, not just a hot quarter. ALEX: On the wealth management side, there was also a good exchange about competition. Steven Chubak asked about smaller RIAs undercutting on price to win workplace clients. Sharon's response was essentially: scale is the moat. Corporate relationships, the breadth o This episode includes AI-generated content.